Table 8 Haplotype analysis of LINC00511 SNPs rs1558535, rs17780195, and rs9906859 in CRC (n = 200).

From: Long intergenic non-coding RNA 00511 (LINC00511) genetic variations and haplotype implication for colorectal cancer susceptibility and prognosis

LINC00511 SNPs

Group, N (%)

FDR adjustment

Haplotype*

CRC, 200

Control, 200

X2

P

OR (95% CI)

Holm

BH

BY

TAC higher risk

63 (31.5%)

48 (24%)

5.61

0.02*

1.46 (1.07—1.99)

0.049*

0.03*

NS

TGC

39 (19.5%)

42 (21%)

0.38

NS

0.90 (0.63—1.27)

0.749

0.54

1.00

AAT

74 (37.0%)

68 (34%)

0.79

NS

1.14 (0.85—1.52)

0.749

0.43

1.00

AAC

15 (7.5%)

20 (10%)

1.87

NS

0.71 (0.43—1.16)

0.514

0.23

0.62

TAT lower risk

3 (1.5%)

16 (8%)

16.8

 < 0.001*

0.20 (0.09—0.47)

 < 0.001*

  1. Global χ2 is 22.6, P < 0.001. Using the Marchov model. * Haplotypes with frequencies less than 0.03 were ignored. Global χ2 = 22.6, P < 0.001. *Alleles in each haplotype are sorted from left to right as rs1558535 A/T, rs17780195 A/G, and rs9906859 T/C. Haplotype phasing is performed by SHEsisPlus, based on partition-ligation-combination- subdivision expectation maximization algorithm (PLCSEM). [BH: Adjusted p-values per the Benjamini and Hochberg procedure, BY: Adjusted p-values per the Benjamini and Yekutieli procedure, FDR: False-Detection Rate, Holm: Holm step-down adjusted p-values, LINC00511: Long intergenic non-coding RNA 50,011, SNP: Single nucleotide polymorphism, NS: Non-significant, OR: Odds ratio, CI: Confidence interval.].
Back to article page